# A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants

> **NCT05445232** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 32 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** LY3437943
- **DRUG:** Midazolam
- **DRUG:** Warfarin
- **DRUG:** Caffeine

## Key facts

- **NCT ID:** NCT05445232
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-08
- **Primary completion:** 2023-02-24
- **Final completion:** 2023-02-24
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05445232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05445232, "A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05445232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*